Truist Securities Maintains Buy on Solid Biosciences, Raises Price Target to $20
Solid Biosciences Inc.
Solid Biosciences Inc. SLDB | 0.00 |
Truist Securities analyst Danielle Brill maintains Solid Biosciences (NASDAQ:
SLDB) with a Buy and raises the price target from $16 to $20.
